AUPH Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
83.7M
+0.6%
83.2M
+7.1%
77.7M
+0.8%
77.1M
+5.0%
73.5M
Cost of Revenue
8.3M
+26.7%
6.6M
+0.8%
6.5M
-26.1%
8.8M
+7.6%
8.2M
Gross Profit
75.4M
-1.7%
76.7M
+7.7%
71.2M
+4.2%
68.3M
+4.6%
65.3M
Operating Expenses
40.0M
+32.0%
30.3M
+1.8%
29.8M
-40.1%
49.7M
+39.8%
35.5M
R&D
16.6M
+27.3%
13.1M
+74.7%
7.5M
-31.4%
10.9M
+29.2%
8.4M
SG&A
24.7M
+5.0%
23.5M
+6.7%
22.0M
-24.7%
29.3M
+11.7%
26.2M
Operating Income
35.4M
-23.7%
46.3M
+11.9%
41.4M
+122.3%
18.6M
-37.4%
29.7M
EBITDA
40.2M
-21.4%
51.2M
+10.7%
46.2M
+96.8%
23.5M
-32.1%
34.6M
Net Income
31.7M
-15.3%
37.4M
+8.9%
34.4M
-83.7%
210.8M
+568.1%
31.6M
EPS (Basic)
$0.24
-17.2%
$0.29
+11.5%
$0.26
-83.8%
$1.60
+566.7%
$0.24
EPS (Diluted)
$0.23
-17.9%
$0.28
+12.0%
$0.25
-83.7%
$1.53
+565.2%
$0.23
Shares (Diluted)
135.2M
+1.2%
133.5M
-3.0%
137.6M
-0.3%
138.1M
+1.5%
136.0M
Aurinia Pharmaceuticals (AUPH) — Financials